Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis
Recursion official investor newsroom · 行业原文收录 · 来源发布:Wed Nov 18 2026 09:59:32 GMT+0000 (Coordinated Universal Time) · 本站收录:Wed Nov 18 2026 10:08:16 GMT+0000 (Coordinated Universal Time)
已保存的原文节选
Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis November 18, 2026 at 4:59 AM EST PDF Version REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through
以上为带出处的原文节选,完整内容请阅读原始链接。自动收录与主题分类不等于事实核验。